These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7925467)

  • 21. 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta.
    Quaedackers ME; Van Den Brink CE; Wissink S; Schreurs RH; Gustafsson JA; Van Der Saag PT; Van Der Burg BB
    Endocrinology; 2001 Mar; 142(3):1156-66. PubMed ID: 11181531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
    Gong Y; Ballejo G; Murphy LC; Murphy LJ
    Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric liver transcription factors LFB1 (HNF1) containing the acidic activation domain of VP16 act as positive dominant interfering mutants.
    Denecke B; Bartkowski S; Senkel S; Klein-Hitpass L; Ryffel GU
    J Biol Chem; 1993 Aug; 268(24):18076-82. PubMed ID: 8394359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone regulates the expression of hepatocyte nuclear factor-3 gamma and other liver-enriched transcription factors in the bovine liver.
    Eleswarapu S; Jiang H
    J Endocrinol; 2005 Jan; 184(1):95-105. PubMed ID: 15642787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
    Paech K; Webb P; Kuiper GG; Nilsson S; Gustafsson J; Kushner PJ; Scanlan TS
    Science; 1997 Sep; 277(5331):1508-10. PubMed ID: 9278514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
    Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W
    Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transactivation of the rat CYP2C13 gene promoter involves HNF-1, HNF-3, and members of the orphan receptor subfamily.
    Legraverend C; Eguchi H; Ström A; Lahuna O; Mode A; Tollet P; Westin S; Gustafsson JA
    Biochemistry; 1994 Aug; 33(33):9889-97. PubMed ID: 8060996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression.
    Kritis AA; Ktistaki E; Barda D; Zannis VI; Talianidis I
    Nucleic Acids Res; 1993 Dec; 21(25):5882-9. PubMed ID: 8290348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver-enriched transcription factors uncoupled from expression of hepatic functions in hepatoma cell lines.
    Chaya D; Fougère-Deschatrette C; Weiss MC
    Mol Cell Biol; 1997 Nov; 17(11):6311-20. PubMed ID: 9343392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interplay between a new HNF3 and the HNF1 transcriptional factors in the duck hepatitis B virus enhancer.
    Crescenzo-Chaigne B; Pillot J; Lilienbaum A
    Virology; 1995 Oct; 213(1):231-40. PubMed ID: 7483267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation.
    McInerney EM; Katzenellenbogen BS
    J Biol Chem; 1996 Sep; 271(39):24172-8. PubMed ID: 8798658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of HNF1alpha, HNF3gamma, and cyclic AMP in glucose-6-phosphatase gene activation.
    Lin B; Morris DW; Chou JY
    Biochemistry; 1997 Nov; 36(46):14096-106. PubMed ID: 9369482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis.
    Philips A; Chalbos D; Rochefort H
    J Biol Chem; 1993 Jul; 268(19):14103-8. PubMed ID: 8314777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
    Dauvois S; Danielian PS; White R; Parker MG
    Proc Natl Acad Sci U S A; 1992 May; 89(9):4037-41. PubMed ID: 1570330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver specific transcription factors of the HNF3-, C/EBP- and LFB1-families interact with the A-activator binding site.
    Drewes T; Klein-Hitpass L; Ryffel GU
    Nucleic Acids Res; 1991 Dec; 19(23):6383-9. PubMed ID: 1754374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic effects of the forced expression of HNF4 and HNF1alpha are conditioned by properties of the recipient cell.
    Bailly A; Späth G; Bender V; Weiss MC
    J Cell Sci; 1998 Aug; 111 ( Pt 16)():2411-21. PubMed ID: 9683635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.
    Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS
    Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An enhancer element 6 kb upstream of the mouse HNF4alpha1 promoter is activated by glucocorticoids and liver-enriched transcription factors.
    Bailly A; Torres-Padilla ME; Tinel AP; Weiss MC
    Nucleic Acids Res; 2001 Sep; 29(17):3495-505. PubMed ID: 11522818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
    Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
    Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.